Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macugen for prevention of proliferative diabetic retinopathy
ISRCTN27864936Phase 4Completed
- Sponsor
- Frimley Health NHS Foundation Trust
- Start
- Jan 2009
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 4, randomised trial of pegaptanib sodium in diabetic retinopathy (DR) and proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Frimley Health NHS Foundation Trust. Primary endpoint: Progression to ETDRS 61. Started Jan 2009; status: completed.
02
Drugs
pegaptanib sodium
03
Conditions
diabetic retinopathy (DR)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ISRCTN27864936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN27864936.